Pemetrexed tromethamine | CAS#1851348-04-3 | chemotherapy drug immpurity

MedKoo Cat#: 597225 | Name: Pemetrexed tromethamine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pemetrexed tromethamine is a chemotherapy drug. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer.

Chemical Structure

Pemetrexed tromethamine

CAS#1851348-04-3 (tromethamine)

Theoretical Analysis

MedKoo Cat#: 597225

Name: Pemetrexed tromethamine

CAS#: 1851348-04-3 (tromethamine)

Chemical Formula: C28H47N7O14

Exact Mass: 0.0000

Molecular Weight: 705.71

Elemental Analysis: C, 47.65; H, 6.71; N, 13.89; O, 31.74

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

357166-29-1 (sodium hydrate) 150399-23-8 (disodium) 137281-23-3 (free acid) 357166-30-4 (sodium 2.5 hydrate) 1851348-04-3 (tromethamine)

Synonym

Pemetrexed tromethamine; Pemetrexed ditromethamine dihydrate;

IUPAC/Chemical Name

2-amino-2-(hydroxymethyl)propane-1,3-diol hemi((4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzoyl)-L-glutamate) dihydrate

InChi Key

DUORKVZYABUEHW-AHJYMZSGSA-N

InChi Code

1S/C20H21N5O6.2C4H11NO3.2H2O/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27;2*5-4(1-6,2-7)3-8;;/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29);2*6-8H,1-3,5H2;2*1H2/t13-;;;;/m0..../s1

SMILES Code

NC1=Nc2c(C(N1)=O)c(CCc3ccc(C(N[C@H](C(O)=O)CCC(O)=O)=O)cc3)c[nH]2.NC(CO)(CO)CO.NC(CO)(CO)CO.O.O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 705.71 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Lin L, Zhao J, Hu J, Zou G, Huang F, Han J, He Y, Cao X. Current Smoking has a Detrimental Effect on Survival for Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) negative Advanced non-squamous Non-small Cell Lung Cancer (NSCLC) Patients Treated with Pemetrexed Continuation Maintenance. J Cancer. 2018 May 25;9(12):2140-2146. doi: 10.7150/jca.24872. eCollection 2018. PubMed PMID: 29937933; PubMed Central PMCID: PMC6010680. 2: Tang J, Li XY, Liang JB, Wu, Peng L, Li X. Copyright © 2018 Cognizant Communication Corporation. Oncol Res. 2018 Jun 21. doi: 10.3727/096504018X15288447760357. [Epub ahead of print] PubMed PMID: 29929572. 3: Taniguchi Y, Horiuchi H, Morikawa T, Usui K. Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report. Case Rep Oncol. 2018 May 29;11(2):323-329. doi: 10.1159/000489603. eCollection 2018 May-Aug. PubMed PMID: 29928211; PubMed Central PMCID: PMC6006630. 4: Chapman D, Taj A. Pemetrexed-Induced Syncope. Am J Ther. 2018 Jun 15. doi: 10.1097/MJT.0000000000000803. [Epub ahead of print] PubMed PMID: 29927772. 5: Pangeni R, Choi JU, Panthi VK, Byun Y, Park JW. Enhanced oral absorption of pemetrexed by ion-pairing complex formation with deoxycholic acid derivative and multiple nanoemulsion formulations: preparation, characterization, and in vivo oral bioavailability and anticancer effect. Int J Nanomedicine. 2018 Jun 6;13:3329-3351. doi: 10.2147/IJN.S167958. eCollection 2018. PubMed PMID: 29922055; PubMed Central PMCID: PMC5995301. 6: Xu D, Liang SQ, Yang H, Lüthi U, Riether C, Berezowska S, Marti TM, Hall SRR, Bruggmann R, Kocher GJ, Schmid RA, Peng RW. Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma. Br J Cancer. 2018 Jun 20. doi: 10.1038/s41416-018-0145-3. [Epub ahead of print] PubMed PMID: 29921948. 7: Xu H, Xu F, Zhu W, Ying J, Wang Y. Comparing first-line treatment patterns and clinical outcomes of patients with pan-negative advanced non-squamous non-small cell lung cancer. Thorac Cancer. 2018 Jun 19. doi: 10.1111/1759-7714.12777. [Epub ahead of print] PubMed PMID: 29917332. 8: Petri GL, Cascioferro S, Parrino B, Peters GJ, Diana P, Giovannetti E. Proton-coupled folate transporter as a biomarker of outcome to treatment for pleural mesothelioma. Pharmacogenomics. 2018 Jun 19. doi: 10.2217/pgs-2018-0071. [Epub ahead of print] PubMed PMID: 29916298. 9: Müller C, Guzik P, Siwowska K, Cohrs S, Schmid RM, Schibli R. Combining Albumin-Binding Properties and Interaction with Pemetrexed to Improve the Tissue Distribution of Radiofolates. Molecules. 2018 Jun 16;23(6). pii: E1465. doi: 10.3390/molecules23061465. PubMed PMID: 29914162. 10: Alshangiti A, Chandhoke G, Ellis PM. Antiangiogenic therapies in non-small-cell lung cancer. Curr Oncol. 2018 Jun;25(Suppl 1):S45-S58. doi: 10.3747/co.25.3747. Epub 2018 Jun 13. Review. PubMed PMID: 29910647; PubMed Central PMCID: PMC6001774. 11: Nishimoto K, Karayama M, Inui N, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inami N, Matsuura S, Kaida Y, Matsui T, Asada K, Matsuda H, Fujii M, Toyoshima M, Imokawa S, Suda T. Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study. Med Oncol. 2018 Jun 16;35(7):108. doi: 10.1007/s12032-018-1172-x. PubMed PMID: 29909581. 12: Carneiro-Leão L, Barzylovych V, Cernadas J. Pemetrexed anaphylaxis - an unusual suspect. J Allergy Clin Immunol Pract. 2018 Jun 13. pii: S2213-2198(18)30392-1. doi: 10.1016/j.jaip.2018.06.004. [Epub ahead of print] PubMed PMID: 29908333. 13: Mahmud F, Jeon OC, Alam F, Maharjan R, Choi JU, Park J, Lee S, Park JW, Lee DS, Byun Y. Oral pemetrexed facilitates low-dose metronomic therapy and enhances antitumor efficacy in lung cancer. J Control Release. 2018 Jun 13. pii: S0168-3659(18)30364-X. doi: 10.1016/j.jconrel.2018.06.018. [Epub ahead of print] PubMed PMID: 29908222. 14: Laslett NF, Park S, Masters GA, Biggs DD, Schneider CJ, Misleh JG, Suppiah K, Simpson PS, Grubbs S, Wozniak TF, Guarino M. Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non-small-cell lung cancer. Cancer Med. 2018 Jun 14. doi: 10.1002/cam4.1569. [Epub ahead of print] PubMed PMID: 29905018. 15: Bittoni MA, Arunachalam A, Li H, Camacho R, He J, Zhong Y, Lubiniecki GM, Carbone DP. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study. Clin Lung Cancer. 2018 May 7. pii: S1525-7304(18)30099-8. doi: 10.1016/j.cllc.2018.04.017. [Epub ahead of print] PubMed PMID: 29885945. 16: Park S, Ahn BC, Lim SW, Sun JM, Kim HR, Hong MH, Lee SH, Ahn JS, Park K, Choi Y, Cho BC, Ahn MJ. Characteristics and outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. J Thorac Oncol. 2018 Jun 5. pii: S1556-0864(18)30673-7. doi: 10.1016/j.jtho.2018.05.026. [Epub ahead of print] PubMed PMID: 29883837. 17: Thawani R, Thomas A, Thakur K. Tracheomediastinal Fistula: Rare Complication of Treatment with Bevacizumab. Cureus. 2018 Apr 3;10(4):e2419. doi: 10.7759/cureus.2419. PubMed PMID: 29872599; PubMed Central PMCID: PMC5985921. 18: Hill J, Vargo C, Smith M, Streeter J, Carbone DP. Safety of dose-reduced pemetrexed in patients with renal insufficiency. J Oncol Pharm Pract. 2018 Jan 1:1078155218780507. doi: 10.1177/1078155218780507. [Epub ahead of print] PubMed PMID: 29871545. 19: Severi L, Losi L, Fonda S, Taddia L, Gozzi G, Marverti G, Magni F, Chinello C, Stella M, Sheouli J, Braicu EI, Genovese F, Lauriola A, Marraccini C, Gualandi A, D'Arca D, Ferrari S, Costi MP. Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer. Front Pharmacol. 2018 May 8;9:454. doi: 10.3389/fphar.2018.00454. eCollection 2018. PubMed PMID: 29867465; PubMed Central PMCID: PMC5952181. 20: Baxevanos P, Mountzios G. Novel chemotherapy regimens for advanced lung cancer: have we reached a plateau? Ann Transl Med. 2018 Apr;6(8):139. doi: 10.21037/atm.2018.04.04. Review. PubMed PMID: 29862228; PubMed Central PMCID: PMC5952027.